Brokerages expect that Tyme Technologies, Inc. (NASDAQ:TYME) will post ($0.06) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Tyme Technologies’ earnings. Tyme Technologies reported earnings of ($0.04) per share during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The firm is scheduled to report its next earnings results on Wednesday, May 19th.
According to Zacks, analysts expect that Tyme Technologies will report full-year earnings of ($0.25) per share for the current financial year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.20) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Tyme Technologies.
Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings results on Thursday, February 4th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.
In other Tyme Technologies news, major shareholder Steve Hoffman sold 83,500 shares of the firm’s stock in a transaction dated Wednesday, April 28th. The stock was sold at an average price of $1.57, for a total value of $131,095.00. Also, major shareholder Michael Demurjian sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 1st. The shares were sold at an average price of $2.10, for a total value of $42,000.00. Insiders have sold a total of 408,750 shares of company stock worth $730,430 in the last three months. 25.51% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Tyme Technologies by 78.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 39,474 shares of the company’s stock valued at $37,000 after acquiring an additional 17,384 shares in the last quarter. Personal CFO Solutions LLC bought a new position in shares of Tyme Technologies during the 1st quarter valued at about $52,000. Rhumbline Advisers increased its position in shares of Tyme Technologies by 5.6% during the 4th quarter. Rhumbline Advisers now owns 96,581 shares of the company’s stock valued at $118,000 after purchasing an additional 5,100 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Tyme Technologies by 3.2% during the 4th quarter. Nuveen Asset Management LLC now owns 378,776 shares of the company’s stock valued at $462,000 after purchasing an additional 11,716 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Tyme Technologies by 6.0% during the 4th quarter. BlackRock Inc. now owns 4,454,185 shares of the company’s stock valued at $5,433,000 after purchasing an additional 250,552 shares during the last quarter. 13.01% of the stock is currently owned by hedge funds and other institutional investors.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.
Featured Article: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.